Estrella Immunopharma (ESLA) Change in Accured Expenses (2022 - 2026)

Estrella Immunopharma (ESLA) has reported Change in Accured Expenses for 5 consecutive years, with -$59332.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 104.37% year-over-year to -$59332.0; the TTM figure through Mar 2026 stood at $8.2 million (up 21.4% YoY), while the FY2025 annual figure was $9.6 million, up 245.48% from the prior year.
• Change in Accured Expenses slipped to -$59332.0 in Q1 2026 per ESLA's latest filing, from $9.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $9.7 million in Q4 2025 and bottomed at -$6.1 million in Q3 2025.
• Historically, Change in Accured Expenses has averaged $892693.9 across 5 years, with a median of $65598.0 in 2023.
• On a YoY basis, Change in Accured Expenses climbed as much as 137200.0% in 2024 and fell as far as 424.59% in 2024.
• Estrella Immunopharma's Change in Accured Expenses stood at $18153.0 in 2022, then surged by 261.36% to $65598.0 in 2023, then soared by 4142.0% to $2.8 million in 2024, then jumped by 249.77% to $9.7 million in 2025, then plunged by 100.61% to -$59332.0 in 2026.
• Business Quant data shows ESLA's Change in Accured Expenses at -$59332.0 in Q1 2026, $9.7 million in Q4 2025, and -$6.1 million in Q3 2025.